(Finance) – Svas Biosana registered a revenue consolidated as at 30 June 2022, not subject to statutory audit, which amounted to 43.8 million euros, up 13.6% compared to the same period of the previous year (approximately 38.6 million) with a double digit increase of consolidated revenues in almost all areas in which the Group operates.
“We are fully satisfied with the revenues achieved during the first half of the year which recorded a 14% increase at consolidated level and double-digit growth in almost all business areas, confirming the solid foundations and the clear strategic vision of the Group in a still highly volatile economic scenario, “he said Umberto Perillo, Chief Executive Officer of Svas Biosana.